Literature DB >> 24889415

Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤ 3 cm: accuracy and interobserver agreement.

Yi-Chen Yeh1,2,3, Jun-ichi Nitadori1,4, Kyuichi Kadota1, Akihiko Yoshizawa1, Natasha Rekhtman5, Andre L Moreira5, Camelia S Sima6, Valerie W Rusch1, Prasad S Adusumilli1,7, William D Travis5.   

Abstract

AIMS: The IASLC/ATS/ERS classification of lung adenocarcinoma provides a prognostically significant histological subclassification. The aim of this study was to investigate the accuracy, limitations and interobserver agreement of frozen sections for predicting histological subtype. METHODS AND
RESULTS: Frozen section and permanent section slides from 361 resected stage I lung adenocarcinomas ≤ 3 cm in size were reviewed for predominant histological subtype and the presence or absence of lepidic, acinar, papillary, micropapillary and solid patterns. Fifty cases were additionally reviewed by three pathologists to determine interobserver agreement. To test the accuracy of frozen section in judging degree of invasion, five pathologists reviewed frozen section slides from 35 cases with a predominantly lepidic pattern. There was moderate agreement on predominant histological subtype between frozen sections and final diagnosis (κ = 0.565). Frozen sections had high specificity for micropapillary and solid patterns (94% and 96%, respectively), but sensitivity was low (37% and 69%, respectively). The interobserver agreement was satisfactory (κ > 0.6, except for the acinar pattern).
CONCLUSIONS: Frozen section can provide information on the presence of aggressive histological patterns-micropapillary and solid-with high specificity but low sensitivity. It was difficult to predict the predominant pattern on the basis of frozen sections, mostly because of sampling issues.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  frozen sections; histological subtype; invasion; limited resection; lung adenocarcinoma; micropapillary; solid

Mesh:

Year:  2015        PMID: 24889415      PMCID: PMC4536823          DOI: 10.1111/his.12468

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  48 in total

1.  Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas.

Authors:  Arne Warth; Albrecht Stenzinger; Ann-Christin von Brünneck; Benjamin Goeppert; Judith Cortis; Iver Petersen; Hans Hoffmann; Philipp A Schnabel; Wilko Weichert
Journal:  Eur Respir J       Date:  2012-03-09       Impact factor: 16.671

2.  Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.

Authors:  Jun-ichi Nitadori; Adam J Bograd; Kyuichi Kadota; Camelia S Sima; Nabil P Rizk; Eduardo A Morales; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  J Natl Cancer Inst       Date:  2013-08-07       Impact factor: 13.506

3.  American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer.

Authors:  Jessica Donington; Mark Ferguson; Peter Mazzone; John Handy; Matthew Schuchert; Hiran Fernando; Billy Loo; Michael Lanuti; Alberto de Hoyos; Frank Detterbeck; Arjun Pennathur; John Howington; Rodney Landreneau; Gerard Silvestri
Journal:  Chest       Date:  2012-12       Impact factor: 9.410

4.  Root cause analysis of problems in the frozen section diagnosis of in situ, minimally invasive, and invasive adenocarcinoma of the lung.

Authors:  Ann E Walts; Alberto M Marchevsky
Journal:  Arch Pathol Lab Med       Date:  2012-12       Impact factor: 5.534

5.  Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung.

Authors:  Y Yamato; M Tsuchida; T Watanabe; T Aoki; N Koizumi; H Umezu; J Hayashi
Journal:  Ann Thorac Surg       Date:  2001-03       Impact factor: 4.330

6.  Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance.

Authors:  Mitual B Amin; Pheroze Tamboli; Shakil H Merchant; Nelson G Ordóñez; Jungsil Ro; Alberto G Ayala; Jae Y Ro
Journal:  Am J Surg Pathol       Date:  2002-03       Impact factor: 6.394

7.  Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

Authors:  Akihiko Yoshizawa; Shinji Sumiyoshi; Makoto Sonobe; Masashi Kobayashi; Masakazu Fujimoto; Fumi Kawakami; Tatsuaki Tsuruyama; William D Travis; Hiroshi Date; Hironori Haga
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

8.  Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.

Authors:  Terumoto Koike; Teruaki Koike; Katsuo Yoshiya; Masanori Tsuchida; Shin-ichi Toyabe
Journal:  J Thorac Cardiovasc Surg       Date:  2013-08       Impact factor: 5.209

9.  Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.

Authors:  Kyuichi Kadota; Jonathan Villena-Vargas; Akihiko Yoshizawa; Noriko Motoi; Camelia S Sima; Gregory J Riely; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

10.  Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis.

Authors:  Tatsu Miyoshi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Takayuki Shirakusa; Eiju Tsuchiya; Yuichi Ishikawa
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

View more
  49 in total

1.  Intraoperative subtyping of lung adenocarcinoma: an unmet need.

Authors:  Nurlan Aliyev; Yusuke Takahashi; Shaohua Lu; Marissa Mayor; Prasad S Adusumilli
Journal:  Transl Cancer Res       Date:  2016-04-19       Impact factor: 1.241

2.  Clinicopathologic correlates of postoperative N1 or N2 nodal upstaging in non-small cell lung cancer.

Authors:  Youngkyu Moon; Kyo Young Lee; Kyung Soo Kim; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  Prognostic contribution of non-predominant solid and micropapillary components in lung adenocarcinomas.

Authors:  Masaki Suzuki; Tomoyuki Yokose; Haruhiko Nakayama
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

4.  How to deal with subcentimeter lung cancer: a moving target!

Authors:  Paul E Van Schil
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

5.  CT-Guided Core Biopsy for Peripheral Sub-solid Pulmonary Nodules to Predict Predominant Histological and Aggressive Subtypes of Lung Adenocarcinoma.

Authors:  Ping-Chung Tsai; Yi-Chen Yeh; Po-Kuei Hsu; Chun-Ku Chen; Teh-Ying Chou; Yu-Chung Wu
Journal:  Ann Surg Oncol       Date:  2020-05-03       Impact factor: 5.344

6.  Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma.

Authors:  Raj G Vaghjiani; Yusuke Takahashi; Takashi Eguchi; Shaohua Lu; Koji Kameda; Zachary Tano; Jordan Dozier; Kay See Tan; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2020-01-30       Impact factor: 15.609

7.  Pure ground-glass opacity on chest computed tomography: predictive factors for invasive adenocarcinoma.

Authors:  Youngkyu Moon; Sook Whan Sung; Kyo Young Lee; Sung Bo Sim; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 8.  Histopathologic and molecular approach to staging of multiple lung nodules.

Authors:  Frank Schneider; Sanja Dacic
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 9.  Spread through air spaces (STAS): a comprehensive update.

Authors:  Arne Warth
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 10.  Recent clinical innovations in thoracic surgery in Hong Kong.

Authors:  Ze-Rui Zhao; Zheng Li; Dong-Rong Situ; Calvin S H Ng
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.